Cellular Biomedicine launched a Phase II clinical trial for AlloJoin® off-the-shelf allogenic human adipose-derived mesenchymal progenitor cell (haMPC) therapy for knee osteoarthritis.
The trial will recruit 108 patients at six class 3AAA hospitals in China. The status of 3AAA indicates a highly-specialized facility in China’s three-tier classification system, with the most advanced facilities.
This represents the first Phase II clinical trial to treat knee osteoarthritis that has been permitted since the National Medicinal Products Administration clarified its cell therapy regulations in 2017.
The company has also developed ReJoin® haMPC therapy for knee osteoarthritis, which is in a Phase II trial in China under an Investigational New Drug application.
Cellular Biomedicine launched a Phase II clinical trial for AlloJoin® off-the-shelf allogenic human adipose-derived mesenchymal progenitor cell (haMPC) therapy for knee osteoarthritis.
The trial will recruit 108 patients at six class 3AAA hospitals in China. The status of 3AAA indicates a highly-specialized facility in China's three-tier...
Cellular Biomedicine launched a Phase II clinical trial for AlloJoin® off-the-shelf allogenic human adipose-derived mesenchymal progenitor cell (haMPC) therapy for knee osteoarthritis.
The trial will recruit 108 patients at six class 3AAA hospitals in China. The status of 3AAA indicates a highly-specialized facility in China’s three-tier classification system, with the most advanced facilities.
This represents the first Phase II clinical trial to treat knee osteoarthritis that has been permitted since the National Medicinal Products Administration clarified its cell therapy regulations in 2017.
The company has also developed ReJoin® haMPC therapy for knee osteoarthritis, which is in a Phase II trial in China under an Investigational New Drug application.
Copy to clipboard 
